BBP-321 is under clinical development by BridgeBio Pharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect BBP-321’s likelihood of approval (LoA) and phase transition for Benign Familial Pemphigus (Hailey-Hailey Disease) took place on 06 Apr 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their BBP-321 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

BBP-321 overview

BBP-321 (LX2931, LX3305) is under development for the treatment of cystic fibrosis, Darier’s disease (keratosis follicularis) and Hailey-Hailey disease. The drug candidate is administered orally. The drug candidate targets sphingosine-1-phosphate (S1P) lyase, which is important for modulating the immune system by controlling S1P levels in lymphoid tissues. It was also under development for the treatment of rheumatoid arthritis and Duchenne muscular dystrophy.

BridgeBio Pharma overview

BridgeBio Pharma (BridgeBio) is a clinical-stage biotechnology company that develops novel medicines for genetic diseases. The company’s pipeline product portfolio includes precision cardiorenal drugs such as acoramidis, encaleret, BBP-711; mendelian disease drugs which include acoramidis, fosdenopterin, patidegib topical gel, low-dose infigratnib, BBP-589, BBP-551, BBP-418, BBP-681, BBP-671, among others; precision oncology drugs which include high-dose infigratinib, BBP-398, BBP-454, BBP-954. BridgeBio also carries out various phases of clinical trials such as pre-clinical, phase I, phase II studies. The company’s academic partners which include Medical University of South Carolina, University of Pittsburgh, Oregon Health, and Science University, among others. Its industry partners which include Helsinn, Alexion, Bristol Myers Squibb, among others. BridgeBio is headquartered in Palo Alto, California, the US.

Quick View BBP-321 LOA Data

Report Segments
  • Innovator
Drug Name
  • BBP-321
Administration Pathway
  • Oral
Therapeutic Areas
  • Genetic Disorders
  • Immunology
  • Respiratory
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.